Large-cap Health Care company BioMarin Pharmaceutical has logged a 8.0% change today on a trading volume of 3,861,927. The average volume for the stock is 2,484,551.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Based in San Rafael, United States the company has 3,401 full time employees and a market cap of $16,538,572,800.
The company is now trading -20.0% away from its average analyst target price of $108.59 per share. The 25 analysts following the stock have set target prices ranging from $72.0 to $140.0, and on average give BioMarin Pharmaceutical a rating of buy.
Over the last 12 months BMRN shares have declined by -6.8%, which represents a difference of -24.1% when compared to the S&P 500. The stock's 52 week high is $99.56 per share and its 52 week low is $73.68. Based on BioMarin Pharmaceutical's average net margin growth of 15.6% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 2,419,226 | 167,645 | 7 | 0.0 |
| 2022 | 2,096,039 | 141,561 | 7 | 333.33 |
| 2021 | 1,846,275 | -64,080 | -3 | -106.52 |
| 2020 | 1,860,455 | 854,029 | 46 | 4700.0 |
| 2019 | 1,704,048 | -23,848 | -1 | 80.0 |
| 2018 | 1,491,212 | -77,211 | -5 |
